The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2013A New Pharmaceutical Target for Mono and Add-on Therapy in Parkinson’s Disease
Objective/Rationale:
We are targeting a molecule, for the first time in Parkinson’s research, that is only present in the human brain’s motor circuitry and that we believe will respond to... -
Fast Track, 2002Comparitive gene expression analysis of the brain in Parkinson's Disease and in familial encephalopathy with neuroserpin inclusion bodies (FENIB): implications for pathogenesis
Parkinson's disease (PD) is a common neurological disorder that affects the control of movement and frequently cognition. Examination of postmortem brain tissue from subjects with Parkinson's disease...
-
Research Grant, 2024Qualitative Evaluation of Draft Questionnaires for Patient-reported Outcome Measures of Non-motor Symptoms in Early-stage Parkinson's Disease
Study Rationale: This project seeks to address an unmet need for fit-for-purpose, clinical outcome assessments for early-stage Parkinson’s disease (PD) to be used in clinical trials to capture the...
-
Research Grant, 2024Quantification of Three Previously Identified Biomarkers of Progression in Stage 2/3 of Parkinson’s Disease
Study Rationale: Early indicators for Parkinson’s disease (PD), so-called biomarkers, are needed to identify subjects at risk during the earliest, prodromal stages of disease and to support clinical...
-
Research Grant, 2024Assessment of Longitudinal Imaging Using Radiolabeled AV-133 in Early and Prodromal Parkinson’s Disease
Study Rationale: The clinical phase of Parkinson’s disease (PD) is preceded by a prodromal phase of progressing neurodegeneration that can last many years. Imaging markers such as radiolabeled AV-133...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Evaluation of “PDRepair,” a Novel Neuroprotective and Neurorestorative Therapeutic for GBA1-associated Parkinson’s Disease
Study Rationale: Mutations in the GBA1 gene, which encodes an enzyme called GCase, is the strongest genetic risk factor for Parkinson’s Disease (PD) and most often results in the production of GCase...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.